SPRINGWORKS THERAPEUTICS, INC. (SWTX) News

SPRINGWORKS THERAPEUTICS, INC. (SWTX): $31.88

0.19 (+0.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SWTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter SWTX News Items

SWTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SWTX News Highlights

  • SWTX's 30 day story count now stands at 6.
  • Over the past 16 days, the trend for SWTX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • ROSE, CONN and RARE are the most mentioned tickers in articles about SWTX.

Latest SWTX News From Around the Web

Below are the latest news stories about SPRINGWORKS THERAPEUTICS INC that investors may wish to consider to help them evaluate SWTX as an investment opportunity.

How did SpringWorks Therapeutics Inc. (SWTX) fare last session?

The share price of SpringWorks Therapeutics Inc. (NASDAQ:SWTX) rose to $28.09 per share on Tuesday from $27.55. While SpringWorks Therapeutics Inc. has overperformed by 1.96%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SWTX fell by -48.21%, with highs and lows ranging from $65.92 to $13.60, […]

US Post News | January 25, 2023

SpringWorks Therapeutics Inc. (NASDAQ: SWTX) Lose -4.03%, Marking A Loss For Bears.

In the last trading session, 1.31 million SpringWorks Therapeutics Inc. (NASDAQ:SWTX) shares changed hands as the company’s beta touched 0.57. With the company’s per share price at $26.41 changed hands at -$1.11 or -4.03% during last session, the market valuation stood at $1.65B. SWTX’s last price was a discount, traded about -149.6% off its 52-week … SpringWorks Therapeutics Inc. (NASDAQ: SWTX) Lose -4.03%, Marking A Loss For Bears. Read More »

Marketing Sentinel | January 10, 2023

SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, will present today at the 41st Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT (10:30 a.m. ET), and a live webcast will be available at ir.springworkstx.com. Ahead of the presentation, the Company highlighted its 2022 accomplishments and announced its a

Yahoo | January 9, 2023

Can you still get a good price for SpringWorks Therapeutics Inc. (SWTX) Shares at this point?

A share of SpringWorks Therapeutics Inc. (NASDAQ:SWTX) closed at $28.43 per share on Wednesday, up from $26.27 day before. While SpringWorks Therapeutics Inc. has overperformed by 8.22%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SWTX fell by -56.57%, with highs and lows ranging from $65.92 […]

US Post News | January 5, 2023

SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 7:30 a.m. PT.

GlobeNewswire | January 3, 2023

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors

STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that the Company has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for nirogacestat, an investigational gamma secretase inhibitor, for the treatment of adults with desmoid tumors.

GlobeNewswire | December 27, 2022

SpringWorks seeks FDA approval of nirogacestat for desmoid tumors

SpringWorks Therapeutics (SWTX) completed the submission of a new drug application ((NDA)) to the U.S

Seeking Alpha | December 27, 2022

SpringWorks Therapeutics Inc. (NASDAQ: SWTX): Can A Stock Be -62.42% Lower Year-To-Date And Still Be A Loser?

SpringWorks Therapeutics Inc. (NASDAQ:SWTX)’s traded shares stood at 0.78 million during the last session. At the close of trading, the stock’s price was $23.29, to imply a decrease of -1.48% or -$0.35 in intraday trading. The SWTX share’s 52-week high remains $72.20, putting it -210.0% down since that peak but still an impressive 41.61% since … SpringWorks Therapeutics Inc. (NASDAQ: SWTX): Can A Stock Be -62.42% Lower Year-To-Date And Still Be A Loser? Read More »

Marketing Sentinel | December 24, 2022

Have you been able to find a good deal on SpringWorks Therapeutics Inc.’s shares?

In Wednesday’s session, SpringWorks Therapeutics Inc. (NASDAQ:SWTX) marked $24.18 per share, up from $23.51 in the previous session. While SpringWorks Therapeutics Inc. has overperformed by 2.85%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SWTX fell by -66.35%, with highs and lows ranging from $74.97 to […]

US Post News | December 1, 2022

SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference

STAMFORD, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference, taking place virtually on Tuesday, November 29, 2022 at 4:20 p.m. ET. To access the live webcast please visit the Events & Presentations pag

Yahoo | November 22, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6334 seconds.